• Boehringer Ingelheim GmbH, of Ingelheim, Germany, enrolled the first patient in its Phase III study (POLO-AML-2) investigating volasertib, a selective polo-like kinase inhibitor, in combination with chemotherapy in patients with acute myeloid leukemia (AML) who are ineligible for intensive therapy.